Hemophilia Prophylaxis in the Era of Non-Factor Therapies Check out our extensive video library (see channel for our latest videos) Abstract Hemophilia treatment has changed dramatically with the introduction of non-factor therapies. This paper examines how these new treatments affect prophylactic care for
Hematology
Breaking Research: MRD Positive Status Predicts Leukemia Outcomes
Breaking Research MRD Positive Status Predicts Leukemia Outcomes Introduction Minimal residual disease (MRD) status has emerged as one of the most powerful prognostic markers in leukemia management, fundamentally transforming how clinicians assess treatment response and long-term outcomes. MRD-positive status profoundly influences survival outcomes, as demonstrated
CRISPR vs Gene Therapy for Sickle Cell: Which Treatment Works Better?
CRISPR vs Gene Therapy for Sickle Cell: Which Treatment Works Better? Introduction Sickle cell disease (SCD) remains one of the most prevalent inherited hematologic disorders globally, affecting millions of individuals across diverse populations. It is estimated that approximately 100,000 people in the United States live
The Spectrum of AI Influence- Comparative Impact Across Medical Specialties
Will AI Replace Pathologists? The Truth from Leading Hematology Labs in 2025
Bone Marrow Differential: Are Traditional Biopsies Becoming Obsolete?
Bone Marrow Differential: Are Traditional Biopsies Becoming Obsolete? Introduction Bone marrow differential analysis represents a cornerstone diagnostic procedure in hematology, offering crucial insights that cannot be obtained through peripheral blood examination alone. Unlike complete blood counts (CBCs), which produce rapid results, a bone
New Frontiers in Sickle Cell Disease: CRISPR-Based Cures
New Frontiers in Sickle Cell Disease: CRISPR-Based Cures Abstract Sickle cell disease (SCD) remains one of the most pressing global health challenges, with an estimated 300,000 infants born annually with the disorder and millions more living with its lifelong complications. The burden of SCD is disproportionately higher in
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix?
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix? Abstract Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, particularly among older adults and patients unfit for intensive chemotherapy. Over the past decade, treatment models have shifted with the advent of venetoclax, a selective BCL-2 inhibitor,
Iron Study Interpretation: Why Traditional Tests Miss Functional Deficiency
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment Please like and subscribe if you enjoyed this video :-) Introduction The treatment landscape for chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, has undergone a major shift with the advent of Bruton’s tyrosine kinase
